Elevated serum α-synuclein autoantibodies in patients with Parkinson’s disease relative to Alzheimer’s disease and controls
Early diagnosis of neurodegenerative diseases is of paramount importance for successful treatment. Lack of sensitive and early biomarkers for diagnosis of diseases like Parkinson’s disease (PD) is a handicapping problem for all movement disorders specialists. Using serum autoimmune antibodies (AI...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Frontiers Media S.A.
2017
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/60803/1/Alpha%20Syneculin%20Frontier.pdf http://irep.iium.edu.my/60803/7/60803_Elevated%20serum_scopus.pdf http://irep.iium.edu.my/60803/ https://www.frontiersin.org/articles/10.3389/fneur.2017.00720/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Early diagnosis of neurodegenerative diseases is of paramount importance for successful
treatment. Lack of sensitive and early biomarkers for diagnosis of diseases
like Parkinson’s disease (PD) is a handicapping problem for all movement disorders
specialists. Using serum autoimmune antibodies (AIAs) against neural proteins is a new
promising strategy to diagnose brain disorders through non-invasive and cost-effective
method. In the present study, we measured the level of AIAs against α-synuclein (α-syn),
which is an important protein involved in the pathogenesis of PD. In our study patients
with PD (46 patients), Alzheimer’s disease (AD) (27 patients) and healthy controls (20
patients) were evaluated according to their sera α-syn AIAs levels. Interestingly, α-syn
AIAs were significantly elevated in PD group compared to AD and healthy controls,
which advocates their use for diagnosis of PD. |
|---|